{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:12:35Z","timestamp":1792156355343,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00921-3","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:12:37Z","timestamp":1777551157000},"page":"1613-1641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05875974","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8729-5224","authenticated-orcid":false,"given":"Logan D.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1599-0858","authenticated-orcid":false,"given":"Chad M.","family":"Ruoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-5654","authenticated-orcid":false,"given":"David T.","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0886-1707","authenticated-orcid":false,"given":"Deborah A.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9564-0901","authenticated-orcid":false,"given":"Teresa L.","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2448-5896","authenticated-orcid":false,"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Todd","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0866-5245","authenticated-orcid":false,"given":"Sarah","family":"Akerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-7751","authenticated-orcid":false,"given":"Alyssa","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"921_CR1","volume-title":"International classification of sleep disorders \u2013 third edition, text revision","author":"American Academy of Sleep Medicine","year":"2023","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders \u2013 third edition, text revision. Darien: American Academy of Sleep Medicine; 2023."},{"issue":"6","key":"921_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5664\/jcsm.27352","volume":"4","author":"A Ozaki","year":"2008","unstructured":"Ozaki A, Inoue Y, Nakajima T, et al. Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med. 2008;4(6):572\u20138.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"921_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5664\/jcsm.5594","volume":"12","author":"NM Flores","year":"2016","unstructured":"Flores NM, Villa KF, Black J, Chervin RD, Witt EA. The humanistic and economic burden of narcolepsy. J Clin Sleep Med. 2016;12(3):401\u20137.","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"921_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.5664\/jcsm.8482","volume":"16","author":"J Acquavella","year":"2020","unstructured":"Acquavella J, Mehra R, Bron M, Suomi JMH, Hess GP. Prevalence of narcolepsy, other sleep disorders, and diagnostic tests from 2013\u20132016: insured patients actively seeking care. J Clin Sleep Med. 2020;16(8):1255\u201363.","journal-title":"J Clin Sleep Med"},{"key":"921_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jsmc.2012.03.013","volume":"7","author":"S Overeem","year":"2012","unstructured":"Overeem S, Reading P, Bassetti CL. Narcolepsy. Sleep Med Clin. 2012;7:263\u201381.","journal-title":"Sleep Med Clin"},{"key":"921_CR6","volume-title":"International classification of sleep disorders \u2013 third edition","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders \u2013 third edition. Darien: American Academy of Sleep Medicine; 2014."},{"issue":"9","key":"921_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.5664\/jcsm.3004","volume":"9","author":"T Roth","year":"2013","unstructured":"Roth T, Dauvilliers Y, Mignot E, et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med. 2013;9(9):955\u201365.","journal-title":"J Clin Sleep Med"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.sleep.2023.12.015","volume":"114","author":"T Roth","year":"2024","unstructured":"Roth T, Dauvilliers Y, Bogan RK, Plazzi G, Black J. Effects of oxybate dose and regimen on disrupted nighttime sleep and sleep architecture. Sleep Med. 2024;114:255\u201365.","journal-title":"Sleep Med"},{"issue":"1","key":"921_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5664\/jcsm.9638","volume":"18","author":"K Maski","year":"2022","unstructured":"Maski K, Mignot E, Plazzi G, Dauvilliers Y. Disrupted nighttime sleep and sleep instability in narcolepsy. J Clin Sleep Med. 2022;18(1):289\u2013304.","journal-title":"J Clin Sleep Med"},{"key":"921_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101488","volume":"58","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ren R, Yang L, et al. Polysomnographic nighttime features of narcolepsy: a systematic review and meta-analysis. Sleep Med Rev. 2021;58:101488.","journal-title":"Sleep Med Rev"},{"key":"921_CR11","unstructured":"Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]. Palo Alto: Jazz Pharmaceuticals, Inc.; 2025."},{"key":"921_CR12","unstructured":"Xywav [Canadian product monograph including patient medication information]. Dublin: Jazz Pharmaceuticals Ireland Ltd.; 2023."},{"issue":"2","key":"921_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17460441.2022.1999226","volume":"17","author":"G Junnarkar","year":"2022","unstructured":"Junnarkar G, Allphin C, Profant J, et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2022;17(2):109\u201319.","journal-title":"Expert Opin Drug Discov"},{"key":"921_CR14","unstructured":"Xyrem\u00ae (sodium oxybate) oral solution, CIII [prescribing information]. Palo Alto: Jazz Pharmaceuticals, Inc.; 2025."},{"key":"921_CR15","unstructured":"Lumryz\u2122 (sodium oxybate) for extended-release oral solution, CIII [prescribing information]. Chesterfield: Avadel CNS Pharmaceuticals; 2024."},{"issue":"25 Suppl 2","key":"921_CR16","first-page":"S76","volume":"129","author":"RH Eckel","year":"2014","unstructured":"Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA\/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S76-99.","journal-title":"Circulation"},{"issue":"3","key":"921_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa206","volume":"44","author":"RK Bogan","year":"2021","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206.","journal-title":"Sleep"},{"key":"921_CR18","volume-title":"The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Version 3","author":"MM Troester","year":"2023","unstructured":"Troester MM, Quan SF, Berry RB, et al. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Version 3. Darien: American Academy of Sleep Medicine; 2023."},{"issue":"4","key":"921_CR19","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-025-00745-7","volume":"14","author":"DA Nichols","year":"2025","unstructured":"Nichols DA, Steininger TL, Fuller DS, et al. A patient-centric clinical trial design to comprehensively evaluate low-sodium oxybate in people with idiopathic hypersomnia or narcolepsy. Neurol Ther. 2025;14(4):1705\u201327.","journal-title":"Neurol Ther"},{"key":"921_CR20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"6","key":"921_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540\u20135.","journal-title":"Sleep"},{"issue":"14","key":"921_CR22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1212\/WNL.0000000000003787","volume":"88","author":"Y Dauvilliers","year":"2017","unstructured":"Dauvilliers Y, Beziat S, Pesenti C, et al. Measurement of narcolepsy symptoms: the Narcolepsy Severity Scale. Neurology. 2017;88(14):1358\u201365.","journal-title":"Neurology"},{"issue":"6","key":"921_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa009","volume":"43","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Barateau L, Lopez R, et al. Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences. Sleep. 2020;43(6):zsaa009.","journal-title":"Sleep"},{"issue":"5","key":"921_CR24","doi-asserted-by":"publisher","first-page":"zsad323","DOI":"10.1093\/sleep\/zsad323","volume":"47","author":"L Barateau","year":"2024","unstructured":"Barateau L, Chenini S, Denis C, et al. Narcolepsy Severity Scale-2 and Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and consequences in narcolepsy type\u00a02. Sleep. 2024;47(5):zsad323.","journal-title":"Sleep"},{"key":"921_CR25","unstructured":"Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS) since last visit. New York: Columbia University Medical Center; 2009 [updated January 14, 2009]. https:\/\/cssrs.columbia.edu\/wp-content\/uploads\/C-SSRS-1-14-09-SinceLastVisit_AU5.1_eng-USori-1.pdf."},{"issue":"9","key":"921_CR26","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.5664\/jcsm.9326","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895\u2013945.","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"921_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5664\/jcsm.27994","volume":"6","author":"J Black","year":"2010","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6(6):596\u2013602.","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"921_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.sleep.2009.05.004","volume":"10","author":"J Black","year":"2009","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10(8):829\u201335.","journal-title":"Sleep Med"},{"issue":"7","key":"921_CR29","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/sleep\/27.7.1327","volume":"27","author":"M Mamelak","year":"2004","unstructured":"Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27(7):1327\u201334.","journal-title":"Sleep"},{"issue":"4","key":"921_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40263-022-00904-6","volume":"36","author":"T Roth","year":"2022","unstructured":"Roth T, Dauvilliers Y, Thorpy MJ, et al. Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase\u00a0III REST-ON trial. CNS Drugs. 2022;36(4):377\u201387.","journal-title":"CNS Drugs"},{"issue":"1","key":"921_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-021-00886-x","volume":"36","author":"GJ Meskill","year":"2022","unstructured":"Meskill GJ, Davis CW, Zarycranski D, Doliba M, Schwartz JC, Dayno JM. Clinical impact of pitolisant on excessive daytime sleepiness and cataplexy in adults with narcolepsy: an analysis of randomized placebo-controlled trials. CNS Drugs. 2022;36(1):61\u20139.","journal-title":"CNS Drugs"},{"issue":"4","key":"921_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/jsr.12468","volume":"26","author":"T Roth","year":"2017","unstructured":"Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2017;26(4):407\u201314.","journal-title":"J Sleep Res"},{"key":"921_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.sleep.2017.07.030","volume":"40","author":"Y Dauvilliers","year":"2017","unstructured":"Dauvilliers Y, Roth T, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Med. 2017;40:53\u20137.","journal-title":"Sleep Med"},{"issue":"7","key":"921_CR34","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/sleep\/27.7.1255","volume":"27","author":"MM Ohayon","year":"2004","unstructured":"Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep. 2004;27(7):1255\u201373.","journal-title":"Sleep"},{"issue":"12","key":"921_CR35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1212\/WNL.0000000000004373","volume":"89","author":"MP Pase","year":"2017","unstructured":"Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017;89(12):1244\u201350.","journal-title":"Neurology"},{"key":"921_CR36","doi-asserted-by":"publisher","unstructured":"Yiallourou S, Baril AA, Wiedner C, et al. Sleep architecture and dementia risk in adults: an analysis of 5 cohorts from the Sleep and Dementia Consortium. Sleep. 2025;48(9):zsaf129. https:\/\/doi.org\/10.1093\/sleep\/zsaf129.","DOI":"10.1093\/sleep\/zsaf129"},{"key":"921_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2024.101976","volume":"77","author":"MJ Thorpy","year":"2024","unstructured":"Thorpy MJ, Siegel JM, Dauvilliers Y. REM sleep in narcolepsy. Sleep Med Rev. 2024;77:101976.","journal-title":"Sleep Med Rev"},{"issue":"1 Pt 2","key":"921_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/sleep\/9.1.159","volume":"9","author":"J Montplaisir","year":"1986","unstructured":"Montplaisir J, Godbout R. Nocturnal sleep of narcoleptic patients: revisited. Sleep. 1986;9(1 Pt 2):159\u201361.","journal-title":"Sleep"},{"key":"921_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101546","volume":"60","author":"A Seifinejad","year":"2021","unstructured":"Seifinejad A, Vassalli A, Tafti M. Neurobiology of cataplexy. Sleep Med Rev. 2021;60:101546.","journal-title":"Sleep Med Rev"},{"issue":"19","key":"921_CR40","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa2405847","volume":"392","author":"Y Dauvilliers","year":"2025","unstructured":"Dauvilliers Y, Plazzi G, Mignot E, et al. Oveporexton, an oral orexin receptor\u00a02-selective agonist, in narcolepsy type\u00a01. N Engl J Med. 2025;392(19):1905\u201316.","journal-title":"N Engl J Med"},{"issue":"5","key":"921_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.14157","volume":"33","author":"F Ingravallo","year":"2024","unstructured":"Ingravallo F, Bassi C, Zenesini C, et al. Sex disparities in clinical features and burden of narcolepsy type\u00a01. J Sleep Res. 2024;33(5):e14157.","journal-title":"J Sleep Res"},{"issue":"2","key":"921_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchp.2025.100573","volume":"25","author":"R Tadrous","year":"2025","unstructured":"Tadrous R, Or D, Murphy N, Quinn G, Slattery L, Broderick J. Physical performance, health-related quality of life and sleepiness severity of an adult outpatient population with narcolepsy: a cross-sectional analysis. Int J Clin Health Psychol. 2025;25(2):100573.","journal-title":"Int J Clin Health Psychol"},{"issue":"1","key":"921_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/15402002.2022.2025805","volume":"21","author":"C Li","year":"2023","unstructured":"Li C, Xie L, Shang S, et al. The impact of symptom severity on health-related quality of life in people with narcolepsy type\u00a01. Behav Sleep Med. 2023;21(1):13\u201321.","journal-title":"Behav Sleep Med"},{"issue":"4","key":"921_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11325-025-03407-y","volume":"29","author":"J Hlodak","year":"2025","unstructured":"Hlodak J, Madarasova Geckova A, Dankulincova Veselska Z, Feketeova E. The burden of narcolepsy symptoms from patients\u2019 perspective: a narrative qualitative study. Sleep Breath. 2025;29(4):231.","journal-title":"Sleep Breath"},{"issue":"5","key":"921_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.sleep.2004.04.003","volume":"5","author":"L Vignatelli","year":"2004","unstructured":"Vignatelli L, D\u2019Alessandro R, Mosconi P, et al. Health-related quality of life in Italian patients with narcolepsy: the SF-36\u00a0health survey. Sleep Med. 2004;5(5):467\u201375.","journal-title":"Sleep Med"},{"issue":"5","key":"921_CR46","first-page":"233","volume":"10","author":"MJ Thorpy","year":"2017","unstructured":"Thorpy MJ, Hiller G. The medical and economic burden of narcolepsy: implications for managed care. Am Health Drug Benefits. 2017;10(5):233\u201341.","journal-title":"Am Health Drug Benefits"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.sleep.2024.09.024","volume":"124","author":"Y Dauvilliers","year":"2024","unstructured":"Dauvilliers Y, Roth T, Bogan R, et al. Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: a post hoc analysis from the phase\u00a03 REST-ON trial. Sleep Med. 2024;124:209\u201316.","journal-title":"Sleep Med"},{"issue":"11","key":"921_CR48","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.mayocp.2024.05.029","volume":"99","author":"RH Ben-Joseph","year":"2024","unstructured":"Ben-Joseph RH, Somers VK, Black J, et al. Increased risk of new-onset hypertension in patients with narcolepsy initiating sodium oxybate: a real-world study. Mayo Clin Proc. 2024;99(11):1710\u201321.","journal-title":"Mayo Clin Proc"},{"key":"921_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.sleep.2021.06.008","volume":"84","author":"MM Ohayon","year":"2021","unstructured":"Ohayon MM, Thorpy MJ, Carls G, et al. The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis. Sleep Med. 2021;84:405\u201314.","journal-title":"Sleep Med"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00921-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00921-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00921-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:29Z","timestamp":1784819489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00921-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00921-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Logan D. Schneider has received personal compensation for serving on advisory boards and speakers bureaus for Avadel, Eisai, and Jazz Pharmaceuticals. Chad M. Ruoff has served as an advisory board member for Jazz Pharmaceuticals, Eisai, Alkermes, and Takeda and has received grant funding from Jazz Pharmaceuticals. David T. Plante is a consultant and advisory board member for Jazz Pharmaceuticals. He has also served as a consultant\/advisory board member for Alkermes, Harmony Biosciences, Takeda, and Centessa, advisory board member for Apnimed, and a consultant for Aditum Bio, LLC, and Teva Pharmaceuticals (Australia). Deborah A. Nichols, Douglas S. Fuller, M. Todd Kirby, Jessica K. Alexander, Marisa Whalen, and Alyssa Cairns are full-time employees of Jazz Pharmaceuticals who, in the course of this employment, have received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. Sarah Akerman is a former full-time employee of Jazz Pharmaceuticals who, in the course of this employment, has received stock options exercisable for, and other stock awards of, ordinary shares of Jazz Pharmaceuticals, plc. Teresa L. Steininger is a former full-time employee and current contract worker for Jazz Pharmaceuticals who has received shares of Jazz Pharmaceuticals, plc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study (\n                      \n                      identifier NCT05875974) was approved by institutional review boards or ethics committees at all sites (protocol approval number Pro00071404; amendment approval numbers MOD01782418, MOD01918961, MOD02130103) and was performed in accordance with the International Conference on Harmonisation Guideline for Good Clinical Practice and the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}